SCHEMBL3824741

SCHEMBL3824741

Cc1cc(C)c(S(=O)(=O)ON2C(=O)c3ccc(C(c4ccc5c(c4)C(=O)N(OS(=O)(=O)c4c(C)cc(C)cc4C)C5=O)(C(F)(F)F)C(F)(F)F)cc3C2=O)c(C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.48
KDM4E B2RXH2 7/20 0.48
HPGD P15428 4/20 0.48
CYP1A2 P05177 3/20 0.48
CYP3A4 P08684 3/20 0.48
CYP2C19 P33261 3/20 0.48
XBP1 P17861 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
ALDH1A1 P00352 6/20 0.46
F2 P00734 4/20 0.46
KMT2A Q03164 8/20 0.43
HTT P42858 2/20 0.43
MEN1 O00255 5/20 0.42
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
VDR P11473 3/20 0.42
MAPK1 P28482 1/20 0.33
RAPGEF4 Q8WZA2 1/20 0.33
CA1 P00915 3/20 0.32
CA2 P00918 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3826650 0.85 VDR (0.60) MAPTKDM4EHPGDCYP1A2CYP3A4
SCHEMBL3822673 0.84 KDM4E (0.42) MAPTKDM4EHPGDCYP1A2CYP3A4
SCHEMBL3824609 0.84 KDM4E (0.66) MAPTKDM4EHPGDCYP1A2CYP3A4
SCHEMBL3823633 0.81 KMT2A (0.37) MAPTKDM4EHPGDCYP1A2CYP3A4
SCHEMBL3824140 0.81 KMT2A (0.46) MAPTKDM4EHPGDCYP1A2CYP3A4
SCHEMBL5557975 0.79 KDM4E (0.73) MAPTKDM4EHPGDCYP1A2CYP3A4
SCHEMBL29761819 0.79 KDM4E (0.73) MAPTKDM4EHPGDCYP1A2CYP3A4
SCHEMBL3823299 0.79 KDM4E (0.62) MAPTKDM4EHPGDCYP1A2CYP3A4
SCHEMBL3824392 0.79 KMT2A (0.62) MAPTKDM4EHPGDCYP1A2CYP3A4
SCHEMBL3824343 0.79 KMT2A (0.51) MAPTKDM4EHPGDCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1449833-B1 BISIMIDE COMPOUND, ACID GENERATOR AND RESIST COMPOSITION EACH CONTAINING THE SAME, AND METHOD OF FORMING PATTERN FROM THE COMPOSITION WAKO PURE CHEM IND LTD (JP) 2009-09-09 EP disclosed
US-7374857-B2 Bismide compound, acid generator and resist composition each containing the same, and method of forming pattern from the composition WAKO PURE CHEMICAL INDUSTRIES LTD. (JP) 2008-05-20 US disclosed
US-20050038261-A1 Bismide compound, acid generator and resist composition each containing the same, and method of forming pattern from the composition WAKO PURE CHEMICAL INDUSTRIES LTD. (JP) 2005-02-17 US disclosed
EP-1449833-A1 BISIMIDE COMPOUND, ACID GENERATOR AND RESIST COMPOSITION EACH CONTAINING THE SAME, AND METHOD OF FORMING PATTERN FROM THE COMPOSITION Wako Pure Chemical Industries, Ltd. (JP) 2004-08-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038261-A1 Bismide compound, acid generator and resist composition each containing the same, and method of forming pattern from the composition ASIC1, GAR1, RER1 MAPT 868/4885KDM4E 2501/4885HPGD 2276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.